NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Down 83.2% in January

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a significant drop in short interest in the month of January. As of January 30th, there was short interest totaling 41 shares, a drop of 83.2% from the January 15th total of 244 shares. Based on an average trading volume of 459 shares, the short-interest ratio is currently 0.1 days. Based on an average trading volume of 459 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On NewAmsterdam Pharma

A hedge fund recently raised its stake in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC boosted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) by 1.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 245,000 shares of the company’s stock after buying an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent SEC filing.

NewAmsterdam Pharma Trading Up 9.6%

NAMSW traded up $1.95 during trading on Tuesday, hitting $22.26. 3,326 shares of the stock traded hands, compared to its average volume of 1,002. NewAmsterdam Pharma has a 12-month low of $5.45 and a 12-month high of $29.99. The firm has a 50-day moving average of $23.15 and a 200 day moving average of $20.86.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.